title: Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor.
abstract: Tumors often target dendritic cells (DCs) to evade host immune surveillance. DC injury is reported in many rodent and human tumors but seldom in tumors of other mammals. Canine transmissible venereal tumor (CTVT), a unique and spontaneous cancer transmitted by means of viable tumor cells. CTVT causes manifold damage to monocyte-derived DCs. This cancer provides an in vivo model of cancer to study the role of monocyte-derived DCs during spontaneous regression. Using flow cytometry and real-time reverse-transcription polymerase chain reactions, we compared the expression of surface molecules on monocyte-derived DCs between normal dogs and dogs with CTVT. These markers were CD1a, CD83, costimulatory factors (CD40, CD80, and CD86), and major histocompatability complex classes I and II. In immature DCs (iDCs) and lipopolysaccharide-treated mature DCs (mDCs), the surface markers were mostly downregulated during tumoral progression and regression. The tumor lowered endocytic activity of iDCs, as reflected in dextran uptake, and decreased allogeneic mixed lymphocyte reactions of mDCs. In addition, it decreased the number of monocytes in the peripheral blood by 40%. The tumor substantially impaired the efficiency with which DCs were generated from monocytes and with which mDCs were generated from iDCs. We also found that progression-phase CTVT supernatants that were cultured for 48 h and that contained protein components killed both monocytes and DCs. Additionally, DC numbers were significantly lower in the draining lymph nodes in CTVT dogs than in normal dogs. In conclusion, CTVT caused devastating damage to monocyte-derived DCs; this might be one of its mechanisms for evading host immunity. Reestablishment of monocyte-derived DC activity by the host potentially might contribute to spontaneous tumoral regression. These findings provide insight into the extent of tumoral effects on host immune systems and responses. This information is useful for developing cancer immunotherapies.
authors: Department of Veterinary Medicine, Animal Cancer Research Center, National Taiwan University, 1, Roosevelt Road, Section 4, 106 Taipei, Taiwan, ROC.
authors: Cheng-Chi
authors: CC
authors: Liu
authors: Yu-Shan
authors: YS
authors: Wang
authors: Ching-Yi
authors: CY
authors: Lin
authors: Tien-Fu
authors: TF
authors: Chuang
authors: Kuang-Wen
authors: KW
authors: Liao
authors: Kwan-Hwa
authors: KH
authors: Chi
authors: Mo-Fan
authors: MF
authors: Chen
authors: Hsin-Chien
authors: HC
authors: Chiang
authors: Rea-Min
authors: RM
authors: Chu
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D002454:Cell Differentiation / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D003713:Dendritic Cells / Q000166:cytology* / Q000378:metabolism*; D004195:Disease Models, Animal; D018450:Disease Progression; D004283:Dog Diseases; D004285:Dogs; D015536:Down-Regulation; D005434:Flow Cytometry; D006649:Histocompatibility Antigens / Q000096:biosynthesis; D006801:Humans; D007959:Lymphocyte Culture Test, Mixed; D016246:Lymphocytes, Tumor-Infiltrating; D009000:Monocytes / Q000166:cytology* / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019139:Tumor Escape / Q000276:immunology*; D014685:Venereal Tumors, Veterinary / Q000276:immunology* / Q000503:physiopathology
chemical_list: D015703:Antigens, CD; D006649:Histocompatibility Antigens
references: Int Immunol. 2000 Nov;12(11):1511-9
references: 11058570
references: Exp Biol Med (Maywood). 2006 Apr;231(4):431-43
references: 16565439
references: J Periodontal Res. 2002 Jun;37(3):177-83
references: 12113551
references: Cancer Immunol Immunother. 2004 Dec;53(12):1093-100
references: 15696609
references: Semin Cancer Biol. 2002 Feb;12(1):33-42
references: 11926410
references: J Immunol. 2002 Mar 1;168(5):2255-63
references: 11859113
references: Nat Med. 2006 Feb;12(2):214-9
references: 16444265
references: J Exp Med. 2002 Feb 4;195(3):343-51
references: 11828009
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: J Immunol. 2006 May 1;176(9):5637-43
references: 16622033
references: Blood. 1998 Dec 15;92(12):4778-91
references: 9845545
references: Br J Cancer. 2003 Oct 20;89(8):1463-72
references: 14562018
references: Int J Cancer. 2001 Dec 15;94(6):825-33
references: 11745485
references: Clin Cancer Res. 2006 Jan 1;12(1):264-72
references: 16397051
references: J Immunol Methods. 2004 Nov;294(1-2):67-80
references: 15604017
references: Immunol Cell Biol. 2005 Oct;83(5):451-61
references: 16174093
references: Vet Immunol Immunopathol. 2003 May 12;92(3-4):149-62
references: 12730015
references: Can J Vet Res. 2007 Jul;71(3):165-74
references: 17695590
references: Eur J Immunol. 2004 Oct;34(10):2800-11
references: 15368296
references: Immunology. 1997 Feb;90(2):294-300
references: 9135560
references: J Immunol. 2005 Sep 1;175(5):3045-52
references: 16116192
references: J Hematother Stem Cell Res. 2003 Oct;12(5):515-23
references: 14594508
references: Pathobiology. 1999;67(5-6):282-6
references: 10725803
references: Curr Opin Immunol. 1997 Feb;9(1):10-6
references: 9039784
references: Adv Exp Med Biol. 1997;417:525-8
references: 9286414
references: Immunol Lett. 1992 Feb;31(2):189-97
references: 1371267
references: J Immunol. 2004 Feb 1;172(3):1508-14
references: 14734728
references: Vet Immunol Immunopathol. 2006 Jan 15;109(1-2):167-76
references: 16202456
references: Biochemistry. 1983 Dec 6;22(25):5692-8
references: 6607069
references: J Hepatol. 1999 Aug;31(2):323-31
references: 10453947
references: J Immunol. 2000 Feb 1;164(3):1269-76
references: 10640740
references: Vet Immunol Immunopathol. 2002 Aug;87(1-2):19-27
references: 12052339
references: Anticancer Res. 2001 Nov-Dec;21(6A):4017-24
references: 11911286
references: Science. 1990 Sep 21;249(4975):1431-3
references: 1698311
references: Mod Pathol. 2001 Jan;14(1):40-5
references: 11211308
references: Adv Cancer Res. 1985;43:75-112
references: 3887857
references: Mol Immunol. 2005 Aug;42(12):1531-40
references: 15950746
references: Clin Immunol. 2004 Dec;113(3):310-7
references: 15507396
references: Cancer Immunol Immunother. 2007 Jan;56(1):48-59
references: 16612596
references: Vet Rec. 1969 Apr 19;84(16):418-9
references: 5815470
references: Transplantation. 2000 Nov 27;70(10):1437-42
references: 11118086
references: Cell. 2006 Aug 11;126(3):477-87
references: 16901782
references: Anticancer Res. 2004 Jul-Aug;24(4):2243-8
references: 15330168
references: Annu Rev Immunol. 2000;18:767-811
references: 10837075
references: Blood. 2001 Dec 15;98(13):3750-6
references: 11739182
references: Cancer Immunol Immunother. 2004 Jun;53(6):543-50
references: 14666382
references: Eur J Immunol. 2006 Jun;36(6):1537-47
references: 16708404
references: Prostate. 2001 Jan 1;46(1):68-75
references: 11170134
references: J Immunol. 2004 Aug 1;173(3):1772-8
references: 15265907